Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2317-2324

  Recchia, Francesco ^a,b,e   Saggio, Gaetano ^a   Cesta, Alisia ^a   Amiconi, Giovanna ^a   Di Blasio, Anna ^a   Candeloro, Giampiero ^a   Valeriani, Maurizio ^c   Tombolini, Vincenzo ^c   Rea, Silvio ^b,d  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Carlo Ferri   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e NONE   (Italy)

Author keywords

Advanced head and neck cancer; Capecitabine; Cisplatin; Docetaxel; Ifosfamide; Radiation therapy

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; IFOSFAMIDE; MESNA; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; SURVIVAL RATE; TAXOIDS;

EID: 33745522488     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. GLOBOCAN 2002. http:/www-dep.iarc.fr.
2. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
3. Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685-1689, 1991.
4. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86: 265-272, 1994.
5. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 356: 767-768, 2000.
6. Recchia F, Sica G, De Filippis S, Rosselli M, Pompili P, Saggio G and Rea S: Chemo-immunotherapy in advanced head and neck cancer. Anticancer Res 19: 773-777, 1999.
7. Amrein PhC and Weitzman SA: Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 3:1632-1639, 1985.
8. Recchia F, Lalli A, Lombardo M, De Filippis S, Saggio G, Fabbri F, Rosselli M, Capomolla E and Rea S: Ifosfamide, cisplatin and 13-cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck. A phase I-II study. Cancer 92: 814-821, 2001.
9. Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Dunnington JS and Hong WK: A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 19: 379-382, 1996.
10. Buesa JM, Fernandez R, Esteban E, Estrada E, Baron FJ, Palacio I, Gracia M and Lacave AJ: Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 2: 151-152, 1991.
11. Verweij J, Alexiera-Figresch J and DeBoer MF: Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 24: 795-796, 1988.
12. Braakhuis BJ, Kegel A and Welters MJ: The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 81: 151-154, 1994.
13. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R and Posner MR: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672-1678, 1996.
14. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M and Clavel M: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 533-537, 1994.
15. Vermorkomen JB, Remenar E, Van Herpen C, Germa Lluch J, Stewart S, Gorlia T, Degardin M, Schollen K and Bernier J: Standard cisplatin /infusional 5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for unresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC. A Head and Neck Cancer Group (EORTC#24971). J Clin Oncol Asco Annual Meeting Proc 22: Abstract 5508, 2004.
16. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y and Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human xenografts. Clin Cancer Res 5: 2948-2953, 1999.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
19. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL and Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 21: 4161-4174, 2003.
20. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA and Posner MR: Docetaxel, cisplatin, and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97: 412-418, 2003.
21. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ and Vokes EE: Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 5: 291-298, 1999.
22. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22: 665, 1979.
23. Grant DS, Williams TL, Zahaczewsky M and Dicker AP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104: 121-129, 2003.
24. ten Tije AJ, Verweij J, Carducci MA et al: Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23: 1070-1077, 2005.
25. Specht L, Larsen SK and Hansen HS: Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 11: 845-984, 2000.
26. Schoffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J and Hanauske AR: Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10: 119-122, 1999.
27. Caponigro F, Massa E, Manzione L, Rosati G, Biglietto M, De Lucia L, Sguotti C, Sganga P, Avallone A, Comella P, Mantovani G and Comella G: Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 12: 199-202, 2001.
28. Baur M, Kienzer HR, Schweiger J, DeSantis M, Gerber E, Pont J, Hudec M, Schratter-Sehn AU, Wicke W and Dittrich C: Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 94: 2953-2958, 2002.
29. Glisson BS, Murphy BA, Frenette G, Khuri FR and Forastiere AA: Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20: 1593-1599, 2002.
30. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R and Garay CA: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19: 1096-1104, 2001.
31. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Marti JL, Lobo F, Pastor P, Valenti V, Belon J, Sanchez MA, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L and Cortes-Funes H: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23: 8636-8645, 2005.